Dapagliflozin Evaluated for Right Ventricular-Pulmonary Artery Coupling Post-OPCAB
The ongoing trial of dapagliflozin in heart failure patients post-surgery could significantly impact its clinical application and market positioning. Positive outcomes may lead to expanded indications, enhancing competitive strategies against other heart failure therapies.
Phase III
Cardiology / Heart Failure
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The ongoing trial of dapagliflozin in heart failure patients post-surgery could significantly impact its clinical application and market positioning. Positive outcomes may lead to expanded indications, enhancing competitive strategies against other heart failure therapies.
Why it matters
The ongoing trial of dapagliflozin in heart failure patients post-surgery could significantly impact its clinical application and market positioning. Positive outcomes may lead to expanded indications, enhancing competitive strategies against other heart failure therapies.
What changed
Trial Update
Analysis
A study is underway to assess the impact of dapagliflozin on right ventricular-pulmonary artery coupling in heart failure patients post-surgery.
The ongoing trial of dapagliflozin in heart failure patients post-surgery could significantly impact its clinical application and market positioning. Positive outcomes may lead to expanded indications, enhancing competitive strategies against other heart failure therapies.
Monitor the trial outcomes, particularly the TAPSE/PASP ratio changes at 7 months.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.